Our results suggest that decreased UBC13 expression predicts a poorer prognosis for ovarian cancer patients and there may be a link between UBC13 expression and paclitaxel sensitivity in ovarian cancer cells. This evidence concerns the gene UBE2N and ovarian cancer.